Related to Convertible Note and Warrant Programmes established on September 26, 2016 between the Fit Biotech Oy and Bracknor Investment the Company’s board of directors has January 20, 2017 resolved to approve Bracknor’s request relating to the funding programme to convert EUR 50,000 worth of Convertible Notes into the Company’s K shares. Due to the conversion of the Convertible Notes, the Company issues 741,784 new K shares in the Company to Bracknor with the conversion price of EUR 0.067405 per share.